Targets › PIWIL1
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Nov 2026.
Endoribonuclease that plays a central role in postnatal germ cells by repressing transposable elements and preventing their mobilization, which is essential for the germline integrity. Acts via the piRNA metabolic process, which mediates the repression of transposable elements during meiosis by forming complexes composed of piRNAs and Piwi proteins and governs the methylation and subsequent repression of transposons. (UniProt, Q96J94)
Open in Phaseline: the race on PIWIL1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Immunocore | IMC-R117C PIWIL1 × CD3 bispecific ImmTAC protein | PIWIL1, CD3E | Phase 1 | Cancer | Nov 2026 |
Cancer (1)
mixed (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.